Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea

Background. Menstrual related migraine (MRM) occurs in 60% of women with migraine. These attacks are characterized by high intensity and poor response to abortive and prophylactic treatment. Hormonal therapy is one of the main treatment methods, but it has a large number of limitations. Increase in...

Full description

Bibliographic Details
Published in:Клинический разбор в общей медицине
Main Authors: Anna V. Berdnikova, Natalya B. Kadymova, Nina V. Latysheva, Margarita V. Naprienko, Elena G. Filatova
Format: Article
Language:English
Published: LLC "MEDIAFORMAT" 2023-10-01
Subjects:
migraine
monoclonal antibodies
erenumab
fremanezumab
cgrp
menstrual-related migraine
Online Access:https://klin-razbor.ru/en/archive/2023/vol-4-10-2023/anti-cgrp-monoclonal-antibodies-in-the-treatment-of-migraine-in-women-impact-on-menstrual-relared-mi_6624/?element

Internet

https://klin-razbor.ru/en/archive/2023/vol-4-10-2023/anti-cgrp-monoclonal-antibodies-in-the-treatment-of-migraine-in-women-impact-on-menstrual-relared-mi_6624/?element

Similar Items